Drug Profile
Tenofovir alafenamide - Gilead Sciences
Alternative Names: GS-7340; GS-7340-02; GS-7340-03; TAF; Tenofovir alafenamide fumarate; VemlidyLatest Information Update: 01 Apr 2024
Price :
$50
*
At a glance
- Originator Gilead Sciences
- Developer Gilead Sciences; University Hospital Inselspital; University of California
- Class Amines; Antivirals; Phosphorus compounds; Propionates; Purines; Small molecules
- Mechanism of Action Nucleotide reverse transcriptase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Marketed Hepatitis B
- Phase III HIV-1 infections
- Phase II HIV infections
Most Recent Events
- 01 Apr 2024 Launched for Hepatitis B (In children) in USA (PO)
- 28 Mar 2024 Registered for Hepatitis B (In children) in USA (PO)
- 10 Nov 2023 Updated efficacy and adverse events data from a phase II trial in Hepatitis B presented at the 74th Annual Meeting of the American Association for the Study of Liver Diseases (AASLD-2023)